Coherus Oncology, Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
CHRS$0.82+6.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 6. Exhibits
Reference is made to the Index to Exhibits included in this Quarterly Report on Form 10-Q.
INDEX TO EXHIBITS
| · · · · Incorporated by Reference · · | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ExhibitNumber | | Description | | Form | | Exhibit | | DateFiled | | FiledHerewith |
| 3.1 | | Amended and Restated Certificate of Incorporation. | | 8-K | | 3.1 | | 11/13/2014 | | |
| | | | | | | | | | | |
| 3.2 | | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Coherus BioSciences, Inc. (the previous name of Coherus Oncology, Inc.), effective as of May 29, 2025 | | 8-K | | 3.1 | | 5/30/2025 | | |
| | | | | | | | | | | |
| 3.3 | | Second Amended and Restated Bylaws of Coherus Oncology, Inc., effective as of May 29, 2025. | | 8-K | | 3.2 | | 5/30/2025 | | |
| | | | | | | | | | | |
| 4.1 | | Reference is made to exhibits 3.1, 3.2 and 3.3. | | | | | | | | |
| | | | | | | | | | | |
| 4.2 | | Form of Common Stock Certificate. | | S-1/A | | 4.2 | | 10/24/2014 | | |
| | | | | | | | | | | |
| 10.1 | | Loan and Security Agreement, dated August 12, 2026, by and among the Company, certain wholly owned subsidiaries of the Company, Innovatus Life Sciences Lending Fund I, LP, as collateral agent, and the lenders party thereto. | | | | | | | | X |
| | | | | | | | | | | |
| 31.1 | | Certification of Principal Executive Officer Required under Securities Exchange Act Rule 13a-14(a) and 15d-14(a). | | | | | | | | X |
| | | | | | | | | | | |
| 31.2 | | Certification of Principal Financial Officer under Securities Exchange Act Rule 13a-14(a) and 15d-14(a). | | | | | | | | X |
| | | | | | | | | | | |
| 32.1* | | Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350 and Securities Exchange Act Rule 13a-14(b). | | | | | | | | |
| | | | | | | | | | | |
| 99.1 | | Contingent Value Rights Agreement, by and between the Company and Equiniti Trust Company, LLC, dated as of August 17, 2026. | | 8-K | | 99.3 | | 8/17/2026 | | |
| | | | | | | | | | | |
| 101 | | The following materials from Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 formatted in iXBRL (Inline eXtensible Business Reporting Language) includes: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations and Comprehensive Income (Loss), (iii) Condensed Consolidated Statements of Stockholders’ Equity (Deficit), (iv) Condensed Consolidated Statements of Cash Flows, and (v) Notes to the Condensed Consolidated Financial Statements. | | | | | | | | X |
| 104 | | Cover page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101). | | | | | | | | X |
*Furnished herewith
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.